BPC-157
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
At a glance
- Peptide
- subcutaneous, oral
- Systematic reviewSystematic review, across 3 audits
- 250 mcg per Peptide Dosing Protocols. All 4 sources
- 10 mg in 2 mL
How much to draw
Full calculator →Opened on 250 mcg, the figure Peptide Dosing Protocols reports for BPC-157, and a 10 mg vial in 2 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for BPC-157 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 250-500 mcg once or twice daily | once or twice daily4-8 weeks · 4-8 week cycles, may repeat after a break | subcutaneous | Commonly published practitioner dosing range - provider confirmation required. |
| Standard: 250 mcg twice daily · Low: 250 mcg once daily · High: 500 mcg twice daily | Twice daily4-6 weeks · Standard | Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHideHalf-life: under 30 minutes. The standard dosing for BPC-157 is 250 mcg twice daily. |
| 250-500 mcg | Twice daily (morning and evening)4-6 weeks | subcutaneous or oral or topical | Peptide Protocol Wiki |
| Referenced at 200-500 mcg (0.2-0.5 mg) daily overall; recovery contexts cite 200-400 mcg once or twice daily, commonly right after training. Oral form referenced as viable for gut-focused use. | 1-2x daily · Morning for systemic or gut focus; post-workout for tissue repair; before bed for overnight healingOn-cycle 4-6 weeks, off-cycle 1-2 months | subcutaneous, intramuscular near injury, or oral | Peptide Therapy Reference TextWhat it saysHideAug 2026), secondary reference; provider confirmation required. |
- once or twice daily4-8 weeks · 4-8 week cycles, may repeat after a break
- subcutaneous
- Commonly published practitioner dosing range - provider confirmation required.
- Twice daily4-6 weeks · Standard
- Subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
Half-life: under 30 minutes. The standard dosing for BPC-157 is 250 mcg twice daily.
- Twice daily (morning and evening)4-6 weeks
- subcutaneous or oral or topical
- Peptide Protocol Wiki
- 1-2x daily · Morning for systemic or gut focus; post-workout for tissue repair; before bed for overnight healingOn-cycle 4-6 weeks, off-cycle 1-2 months
- subcutaneous, intramuscular near injury, or oral
- Peptide Therapy Reference Text
What it saysHide
Aug 2026), secondary reference; provider confirmation required.
- Commonly supplied as 5 mg or 10 mg vials · Reconstitute lyophilized powder with bacteriostatic water; refrigerate after mixing
- 2 mL BAC water
- Bacteriostatic water
BPC-157 and TB-500 Do Different Things on Paper. The Blend Ratio Is Still Somebody's Guess.
Two distinct proposed mechanisms, one shared evidence ceiling, and no published study that tested the pair against either compound alone.
BPC-157 Isn't "Only Rat Studies." It's Tier 2, and That's the Argument You Should Be Having.
The claim everyone repeats is factually wrong and directionally right, here's the evidence ladder that settles it in one question.
BPC-157 Wasn't Banned. It Was Left Off a List.
Four separate regulatory facts get crushed into the word 'legal,' and almost every confident answer online is answering a question you didn't ask.
How it is thought to work
In cell and rodent studies, BPC-157 appears to support angiogenesis, the growth of new blood vessels, and to change how tendon cells behave. Researchers link this to VEGFR2 activation and eNOS/nitric oxide signaling. Direct human evidence is limited to three small pilots with roughly 30 patients in total, and no Phase 2 or Phase 3 randomized trial has been published.
Potential effects on angiogenesis, tissue signaling, and repair pathways.
What we don't know
Whether it works in people: no randomized controlled trial of BPC-157 has been published, and no Phase 2 trial has been completed. Nearly all of the evidence comes from animals and cells, with a small amount of work on human tissue outside the body.
Safety in people: there is no established human safety record. Reviews also describe a possible effect on tumour growth as a theoretical concern that has not been resolved in humans.
Independent checks: nearly every published study reports a positive effect. Our audit says that is not evidence of a problem, but it is a reason to want independent replication before treating the findings as settled.
The pairing with TB-500: our audit could not find a published controlled study that tested the two together against either one alone.
Reported side effects
Seen in studies: a 2025 infusion pilot in two adults at 10 mg and 20 mg found no adverse effects on heart, liver, kidney, thyroid or glucose markers. A 2024 interstitial cystitis pilot and a 2021 knee-pain case series described it as well tolerated in those small samples.
Reported by users: mild redness or small bumps where it is injected.
Not ruled out: an effect on tumour growth, because the blood-vessel growth pathway that supports repair also supports tumours, and reviews call this unresolved. It also affects nitric oxide signaling, which influences blood-vessel tone and so blood pressure. Most material sold in the U.S. is grey-market, so contamination, wrong dosing and degradation are separate practical risks.
Who should avoid it
People with cancer, now or in the past: it promotes blood-vessel growth in animal models, and tumours also depend on new vessels. Reviews call this a theoretical concern that has not been resolved in humans.
People who are pregnant or breastfeeding: no published human reproductive or lactation safety data exists.
Competitive or tested athletes: it has been on the World Anti-Doping Agency Prohibited List under category S0 since 2022 and remains on the 2025 list.
People on blood-pressure medicines: it affects nitric oxide signaling in animal models, which bears on vascular tone.
People seeking a regulated medical treatment: it is not an FDA-approved drug. It was removed from FDA Category 2 as of April 22, 2026. On July 23, 2026 an FDA advisory committee voted 8 to 6, with one abstention, to recommend letting pharmacies compound it. The vote does not bind the FDA, which had made no final decision when it was reported, and it is not an approval.
What gets monitored
Blood pressure monitoring during the research cycle is suggested. (reported by Peptide Dosing Protocols)
Regulatory status
FDA approval: BPC-157 is not approved by the FDA for any use. The reviews we have read tie that to the missing human trials, including no completed Phase 2 trial.
Compounding history: the FDA earlier placed BPC-157 in Category 2, its group of compounding substances flagged for significant safety risk concerns, and pharmacies that had been making it stopped. Our audit says this was not a ban on the substance. The reference entry says BPC-157 was removed from Category 2 as of April 22, 2026.
Advisory committee vote: on July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the list of substances pharmacies may compound. The vote is advisory and does not bind the FDA. Adding a substance to the list needs formal FDA rulemaking, and news reports from July 23 and 24, 2026 said the FDA had made no final decision. FDA staff scientists had objected, citing a lack of safety and effectiveness data. None of this is FDA approval of BPC-157 as a drug.
Sport: the sources behind our own pages disagree about its current World Anti-Doping Agency status, so it is not stated here. The WADA list is reissued every year.
Checked: November 2026.
Common questions
What is BPC-157?
BPC-157 stands for Body Protection Compound 157. It is a lab-made peptide of 15 amino acids, based on a sequence first identified in human gastric juice in the 1990s.
What does BPC-157 do?
In animal studies it supports new blood-vessel growth and helps cells move into injury sites. These findings come from cultured cells and rodents. A 2025 systematic review concluded that human evidence remains insufficient to back clinical guidance.
Is BPC-157 FDA-approved?
No. BPC-157 is not an FDA-approved drug. As of April 22, 2026 it was removed from FDA Category 2. On July 23, 2026 an FDA advisory committee voted 8 to 6, with one abstention, to recommend letting pharmacies compound it. The vote does not bind the FDA, which had made no final decision when it was reported, and it is not an approval.
Why is BPC-157 banned by WADA?
The source says WADA bans substances that lack regulatory approval for human use, and BPC-157 is one of them. It has been on the Prohibited List under category S0 since 2022 and remains on the 2025 list.
How is BPC-157 commonly dosed in research planning?
Reported amounts and schedules for BPC-157 differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
Can BPC-157 be taken orally?
Oral and capsule formats are used in research, especially in gut-focused models. One paper reported that BPC-157 stays stable in human gastric juice for more than 24 hours, which is unusual for a peptide. Direct human evidence remains limited.
How is BPC-157 reconstituted?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
What are the main side effects of BPC-157?
Community reports mention mild redness or small bumps at the injection site. Reviews also flag a theoretical cancer concern, because the blood-vessel growth pathway that supports repair also supports tumour growth. The small human pilots described it as well tolerated.
Sources
- 01Lee et al., Alternative Therapies in Health and Medicine, 2025
- 02Sehgal et al., Pharmaceuticals, 2025
- 03He et al., Frontiers in Pharmacology, 2022
- 04Sikiric et al., Current Pharmaceutical Design, 2011
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
GLOW is a combination sold as one vial, pairing three peptides: GHK-Cu, BPC-157 and TB-500. It is studied for skin quality, tissue repair and recovery, though no trial has tested the three together in people.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.
LL-37 is the active 37-amino-acid piece of the only known human cathelicidin, a natural germ-fighting protein made by white blood cells, skin cells and other tissue linings. It is studied in antimicrobial and innate-immunity research.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
